ArticleStem cell research & therapy2026
Psoralen enhances direct cardiac reprogramming via activating PPARα and driving mitochondrial fission and improves cardiac function after myocardial infarction.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDirect cardiac reprogramming offers a promising strategy to regenerate cardiomyocytes for heart repair, but its efficiency and maturation remain limited. Psoralen, a natural compound isolated from Psoralea corylifolia L., has been widely studied for its bioactive properties. This study aimed to determine whether psoralen enhances chemical cardiac reprogramming and improves functional maturation, and to evaluate its therapeutic potential in myocardial infarction.
methodsMouse embryonic fibroblasts were treated with a chemical reprogramming cocktail containing RepSox and Forskolin, with or without psoralen. Gene expression was assessed by quantitative PCR and Western blotting. Sarcomere ultrastructure was examined by transmission electron microscopy. Mitochondrial content and morphology were analyzed using MitoTracker staining. Calcium handling was evaluated in Fluo-4 loaded induced cardiomyocytes. Metabolic profiles were measured with Seahorse assays. RNA sequencing and protein-protein interaction analysis were used to identify signaling pathways activated by psoralen. To investigate the functional role of mitochondrial fission in psoralen enhanced reprogramming, the DRP1 inhibitor Mdivi-1 was added to the reprogramming cocktail. An immortalized human skin fibroblast cell line was additionally used to evaluate cardiac marker expression and mitochondrial morphology following treatment with RepSox, Forskolin, and psoralen. For in vivo evaluation, a myocardial infarction model was generated in male C57BL/6J mice, which were subsequently treated for 7 days. Cardiac function was measured by echocardiography, and histological changes were assessed by HE and Masson's trichrome staining.
resultsPsoralen (10 µM) significantly increased the induction efficiency of induced cardiomyocytes, leading to the rapid appearance of beating clusters(day 1 vs. day 6-8) and marked upregulation of cardiac structural genes. Psoralen-treated cells displayed enhanced sarcomere organization, improved calcium transients, and a metabolic shift toward oxidative phosphorylation characterized by higher mitochondrial respiration and reduced glycolysis. Transcriptomic profiling identified activation of the PPAR signaling pathway, with PPARα, RXRG, and UCP1 as central nodes. Psoralen also enhanced mitochondrial fission by upregulating fission-related genes and proteins. Mdivi-1 attenuated psoralen-induced cardiac gene expression and mitochondrial fragmentation. In immortalized human skin fibroblasts, psoralen combined with RepSox and Forskolin increased cardiac marker expression and promoted mitochondrial fragmentation. In vivo, psoralen combined with RepSox and Forskolin enhanced cardiac function and reduced fibrosis after myocardial infarction compared to RepSox and Forskolin alone.
conclusionPsoralen enhances chemical direct cardiac reprogramming by activating metabolic and structural maturation programs through mitochondrial fission and PPARα-dependent signaling. The combined treatment provides functional benefits in myocardial infarction, highlighting psoralen as a promising small molecule for cardiac regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.